Conclusions of clinical trials assessing monoclonal antibodies and sponsored by pharmaceutical industry: a meta-research study
Open Access
- 1 January 2024
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (11) , e20241022
Abstract
The objective of this study was to describe and critically appraise the conclusions of randomized clinical trials assessing monoclonal antibodies sponsored by the pharmaceutical industry. This is a meta-research study on conclusions' characteristics of randomized clinical trials with monoclonal antibodies as interventions sponsored by the pharmaceutical industry. A total of 82 publications were considered. Notably, 79.3% (65/82) of the trials were fully funded by the pharmaceutical industry, and sponsors had data and publishing rights in 70.7% (58/82). Among the fully sponsored studies, 78.5% (51/65) presented conclusions with a drug-favorable direction of the effect, and 30.8% (20/65) made some recommendations for clinical practice, of which 95% (19/20) were favorable to the drug. In relation to the partially funded studies, drug-favorable direction of effect was present in 68.8% (11/16) of conclusions, and 18.8% (3/16) recommended the drug for the practice, in which 66.7% (2/3) favored the drug. Positive direction of effect was more present in trials in which the sponsor owned data and publication (81.0%; 47/58), compared to trials where the funder did not (63.3%; 14/22). Only 13.4% (11/82) of included studies recognize the uncertainty in the estimates in the conclusions, and 37.4% (31/82) had a statement regarding the need for future studies. Most of the included randomized clinical trials on monoclonal antibodies funded by the industry concluded a drug-favorable direction of effect. Recommendations for practice were common, while recognition of uncertainty and statements regarding the need for future studies were less frequently present in the conclusion.Keywords
This publication has 14 references indexed in Scilit:
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of FundingJournal of Thoracic Oncology, 2020
- Principles of Clinical Ethics and Their Application to PracticeMedical Principles and Practice, 2020
- Transparent and systematic reporting of meta-epidemiological studiesJournal of Clinical Epidemiology, 2019
- How much do phase III trials cost?Nature Reviews Drug Discovery, 2018
- Guidelines for reporting meta-epidemiological methodology researchBMJ Evidence-Based Medicine, 2017
- Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsorJournal of Clinical Epidemiology, 2015
- Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and TreatmentThe Journal of Allergy and Clinical Immunology: In Practice, 2015
- Publication bias is underreported in systematic reviews published in high-impact-factor journals: metaepidemiologic studyJournal of Clinical Epidemiology, 2014
- Association of Funding and Conclusions in Randomized Drug TrialsJAMA, 2003